World News: 13:00 GMT Monday 14th January 2019. [Rexahn Pharmaceuticals via Globe Newswire via SPi World News]
ROCKVILLE, Md., Jan. 14, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, today announced that it will present updated preliminary safety and efficacy data from the ongoing Phase 2a clinical trial of RX-3117 in combination with ABRAXANE in first-line metastatic pancreatic cancer patients at the 2019 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium being held January 17-19, 2019 at the Moscone West Building in San Francisco, CA.
The poster will be presented on Friday, January 18, 2019 at 11:30 AM-1:00 PM and 5:30 PM-6:30 PM PST. A copy of the poster being presented will be available on the Company's website at beginning at 10:00 AM EST on Friday, January 18, 2019.
Rexahn Pharmaceuticals Inc. (NYSE American: RNN) is a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat. The Company’s mission is to improve the lives of cancer patients by developing next-generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects traditionally associated with cancer treatment. Rexahn’s product candidates work by targeting and neutralizing specific proteins believed to be involved in the complex biological cascade that leads to cancer cell growth. Preclinical studies show that several of Rexahn’s product candidates may be effective against multiple types of cancer, including drug resistant cancers, and difficult-to-treat cancers and others may augment the effectiveness of current FDA-approved cancer treatments. The Company has two oncology product candidates, RX-3117 and RX-5902, in Phase 2 clinical development and additional compounds in preclinical development, including RX-0301. For more information about the Company and its oncology programs, please visit www.rexahn.com.
Globe Newswire: 13:00 GMT Monday 14th January 2019
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.